J&J Shrugs Off Trump Pharma Tariff Threat and Boosts Outlook

Johnson & Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as the pharmaceutical industry faces the dual threats of tariffs and a crackdown on drug pricing.

J&J’s strong second quarter comes as President Donald Trump floats the idea of levies on the sector. On Tuesday night, he said tariffs on drugs could “probably” come at the end of the month, starting low and working their way up.